Skip to main content
Acta Pharmaceutica Sinica. B logoLink to Acta Pharmaceutica Sinica. B
. 2023 Dec 29;14(3):1477. doi: 10.1016/j.apsb.2023.12.014

Author correction to ‘Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects’ [Acta Pharmaceutica Sinica B 13 (2023) 2138–2151]

Wei Wei 1,, Qingxuan Zeng 1,, Yan Wang 1,, Xixi Guo 1, Tianyun Fan 1, Yinghong Li 1, Hongbin Deng 1, Liping Zhao 1, Xintong Zhang 1, Yonghua Liu 1, Yulong Shi 1, Jingyang Zhu 1, Xican Ma 1, Yanxiang Wang 1,, Jiandong Jiang 1,, Danqing Song 1,
PMCID: PMC10935463  PMID: 38486984

The authors regret that there are some misplaced figure numbers in the body of this article due to negligence in the layout and proofreading of the figures. Although it does not affect the conclusion, it is an obvious error. The authors have now modified as below.

The authors apologize for any inconvenience caused to the journal and readers.

  • 1.

    In 2.3. Binding pattern of BBR with EIF2AK2, Fig. 5C should be corrected to Fig. 4C.

  • 2.

    In 2.4. Functional studies of EIF2AK2, Fig. 5D and E, Fig. 5F and G, and Fig. 5H and I should be corrected to Fig. 4D and E, Fig. 4F and G, and Fig. 4H and I, respectively.

Footnotes

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Contributor Information

Yanxiang Wang, Email: wangyanxiang@imb.pumc.edu.cn.

Jiandong Jiang, Email: jiang.jdong@163.com.

Danqing Song, Email: songdanqingsdq@hotmail.com.


Articles from Acta Pharmaceutica Sinica. B are provided here courtesy of Elsevier

RESOURCES